Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC
Dr Alex Spira speaks to ecancer about a global phase I study that evaluates three doses of iza-bren (izalontamab brenitecan), an EGFR and HER3 bispecific antibody drug conjugate, in patients with previously treated EGFR-mutated metastatic NSCLC.
Among 80 patients who had progressed on third-generation EGFR inhibitors, iza-bren achieved an overall response rate of 28.8% and median progression-free survival of 5.4 months.
At the 2.5 mg/kg dose, the overall response rate was 33.3% and median progression-free survival was 6.9 months.
Dr Spira says that grade 3 or higher treatment-related adverse events occurred in 47.5% of patients, most commonly anaemia and neutropenia.
He highlights that the findings support 2.5 mg/kg as the recommended phase III dose, with primary G-CSF prophylaxis helping to manage haematological toxicity.
Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC
Amivantamab plus chemotherapy extends overall survival in EGFR exon 20 insertion NSCLC
JS207 plus chemotherapy enables surgery and deep pathological responses in unresectable NSCLC
Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC
Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management?
Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC
MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer
Durvalumab improves survival and delays progression in limited-stage small cell lung cancer
Osimertinib plus local therapy improves outcomes in EGFR-mutant metastatic lung cancer